文献速递甲状腺疾病

甲状腺癌初始放射性碘治疗影像评估与长期预后

Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该回顾性研究纳入290例甲状腺全切除术后接受初始放射性碘治疗的甲状腺癌患者,依据全身闪烁显像联合形态学影像分为无远处转移、RAI非亲和的远处转移和RAI亲和的远处转移三组。结果显示三组5年生存率分别为98%、86%和82%,7年生存率分别为95%、78%和82%;131I亲和区域的平均计数是PFS的独立预后因素。

要点

  • 初始RAI治疗后影像评估可预测前5年预后。
  • RAI非亲和远处转移组生存率低于RAI亲和组。
  • 131I亲和区域平均计数是PFS独立预后因素。

核心结论

  • 初始RAI治疗的精确影像评估有助于预测前5年预后,支持更有效的综合治疗和长期管理。

研究设计与样本

  • 回顾性研究,纳入2010至2021年间290例甲状腺全切除术后接受初始治疗性RAI的甲状腺癌患者。
  • 依据131I全身闪烁显像联合形态学影像记录分为非远处转移组、RAI非亲和远处转移组和RAI亲和远处转移组。
  • 评估各组无进展生存期和总生存期,并用专用软件自动计算全身闪烁显像的归一化指数。

主要发现

  • 非远处转移组5年和7年生存率分别为98%和95%。
  • RAI非亲和远处转移组5年和7年生存率分别为86%和78%。
  • RAI亲和远处转移组5年和7年生存率分别为82%和82%。
  • 131I亲和区域的平均计数是PFS的显著预后因素,独立于年龄、远处转移模式、组织学亚型和T分类。
  • 转移部位是强预后决定因素,再次治疗宜在初始RAI治疗后2年内进行。

关键数值与推荐

  • 131I亲和病灶定义为摄取超过头颈部、胸部和腹盆腔参考感兴趣区均值加2个标准差。

临床怎么用

  • 对甲状腺癌初始RAI治疗患者应结合全身闪烁显像与形态学影像进行精确评估以预测预后。
  • 关注131I亲和区域平均计数和转移部位以识别高危患者。
  • 对需再次治疗者,考虑在初始RAI治疗后2年内进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Radioactive iodine (RAI) is an established therapy for thyroid cancer (TC). The aim of this study was to evaluate the prognosis and disease characteristics based on initial RAI therapy using image findings. METHODS: We reviewed the clinical records of 290 TC patients who received initial therapeutic RAI therapy following total thyroidectomy for ablation and treatment between 2010 and 2021. Patients were classified into 3 groups based on the 131I whole-body scintigraphy (WBS) combined with morphological imaging records: non-DM, RAI-non-avid DM, and RAI-avid DM. Progression-free survival (PFS) and overall survival were assessed in each group. Normalized indices were calculated automatically using dedicated software for each patient on WBS. 131I-avid lesions were defined as areas with uptake exceeding the mean + 2 SDs of the reference regions of interest placed at the head-cervical, thoracic, and abdominal-pelvis regions, Watabe proposed. RESULTS: The 5-year and 7-year survival rates for the non-DM, RAI-non-avid DM, and RAI-avid DM groups were 98% to 95%, 86% to 78%, and 82% to 82%, respectively. Average count of 131I-avid area was identified as a significant prognostic factor for PFS, being independent of age, distant metastatic pattern, histological subtype, and T classification. Retreatment was preferably performed within 2 years after the initial RAI therapy, as this period appears to be critical for efficacy. Additionally, the site of metastases was a strong prognostic determinant. CONCLUSION: Precise imaging evaluation of the initial RAI therapy may help predict the prognosis during the first 5 years, contributing to more effective comprehensive treatment approaches for long-term management.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Nakatani R, Watabe T, Fukuhara A, et al. Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study. J Clin Endocrinol Metab. 2026. PMID: 41092239. doi:10.1210/clinem/dgaf568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。